Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-04-02

Clinical Trial Update: Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial for EGFR-mutated non-small cell lung cancer (Neo-DIANA) was terminated, with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Fundación GECP | Conditions: Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Status: TERMINATED | Results posted: 2025-04-02